Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia

Leuk Res. 2010 Feb;34(2):154-9. doi: 10.1016/j.leukres.2009.04.027. Epub 2009 May 20.

Abstract

Introduction: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT.

Methods: Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms.

Results: Motor performance was not significantly affected by CYP3A5*3/*3 and CYP3A5*1*3 genotypes, MDR-1 polymorphisms or MAPT haplotype.

Conclusion: Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
  • Child
  • Child, Preschool
  • Cytochrome P-450 CYP3A / genetics*
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Genotype
  • Humans
  • Male
  • Pharmacogenetics
  • Polymorphism, Genetic*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Psychomotor Performance / drug effects*
  • Vincristine / pharmacokinetics*
  • tau Proteins / genetics*

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • MAPT protein, human
  • tau Proteins
  • Vincristine
  • CYP3A5 protein, human
  • Cytochrome P-450 CYP3A